Diabetes impairs cardiac performance more extensively in hypertensive rats than it does in nonhypertensive strains. A "low thyroid state" may contribute to the adverse cardiovascular effects of diabetes in spontaneously hypertensive rats (SHR). We tested this hypothesis by comparing the effects of thyroid hormone with those of insulin treatment on cardiac performance of diabetic SHR. Diabetes was induced with streptozotocin (45 mg/kg). Subsets of diabetic rats were treated with either insulin (10-20 units/kg/day) or triiodothyronine (8-10 /ig/kg/day). Heart rate and systolic arterial pressure were obtained at weekly intervals. After 8 weeks, cardiac function was assessed using an isolated working heart preparation. Diabetes reduced arterial pressure and heart rate in vivo and markedly depressed cardiac performance under volume and pressure loading conditions ex vivo, confirming previous observations. As 4 Chemically induced diabetes in hypertensive rats has a more profound effect on cardiac function than it does in normotensive models.
D
iabetes mellitus is associated with cardiac impairments in humans 1 and in experimental animals. 2 - 3 Both clinical and experimental "diabetic cardiomyopathy" may be exacerbated by hypertension. 4 Chemically induced diabetes in hypertensive rats has a more profound effect on cardiac function than it does in normotensive models. 5 -7 Collectively, the data suggest that pressure loadinduced left ventricular hypertrophy increases the susceptibility of the myocardium to diabetes-related derangements. 1 " 7 Hypothyroidism, or a "low thyroid state," is often reported as a secondary metabolic disorder of diabetes, 8 and insulin replacement therapy has been shown to restore normal thyroid status in diabetic rats. 9 Hypothyroidism and diabetes have a number of similar effects on cardiac metabolism and function. For example, both pathological conditions impair myocardial contractility, depress myosin adenosine triphosphatase (ATPase) activity and sarcoplasmic reticular Ca 2+ uptake, 10 -12 and reduce sensitivity to adrenergic agonists. 13 Whether the cardiovascular effects of diabetes are at least in part due to the attendant low thyroid state has been addressed in a number of studies. Thyroid hormone treatment of normotensive diabetic rats has been shown to be either ineffective 1415 or only partially effective 9 in restoring cardiac function.
Indirect evidence suggests that the influence of an imbalance in thyroid status on the cardiovascular system may have a greater impact in the diabetic spontaneously hypertensive rat (SHR) than it does in diabetic normotensive strains. Thyroidectomy of SHR prevents the onset of elevated systolic arterial pressure, 1617 and either thyroidectomy or methimazole treatment decreases contractility and pressure generation of the isolated working heart. 1617 These effects of hypothyroidism in the SHR strain are reminiscent of, but less pronounced than, those of diabetes. function in the diabetic SHR by comparing the effects of triiodothyronine (T 3 ) treatment with those of insulin therapy. The results add support to the hypothesis that attendant hypothyroidism contributes to the adverse cardiac effects of diabetes in the SHR.
Methods

Animal Groups
Male SHR were obtained from Charles River Breeding Laboratories (Wilmington, Massachusetts), housed communally, and fed ad libitum unless otherwise indicated. At 15 weeks of age, rats were weight matched and earmarked for either nondiabetic or diabetic groups. Diabetes was induced with a single tail vein injection of streptozotocin (STZ), 45 mg/kg body wt (Sigma Chemical Co., St. Louis, Missouri), after rats were lightly anesthetized with ether. The STZ was dissolved in citrate buffer (0.1 M at pH 4.5) just before use. A subset of rats was first injected with 3-O-methylglucose (OMG) (1.2 mmol/ 150 g body wt), followed by STZ within 1 minute. 18 Rats in the nondiabetic groups were also anesthetized with ether and given similar volumes of the citrate buffer alone. Urine glucose levels were estimated using Diastix (Ames, Elkhart, Indiana). Diabetes was confirmed in all rats that received STZ. No urinary glucose was detected in the OMG group.
The following treatment regimens were begun 3 days after the tail vein injections. Diabetic rats were further divided into four subgroups and were treated with one of the following: lente insulin (LI) (Sigma Chemical Co.), 20 units/kg/day s.c; protamine zinc insulin (PZI) (Eli Lilly Co., Indianapolis, Indiana), 10 units/kg/day s.c; or T 3 (Sigma Chemical Co.), 8-10 ^.g/kg/day s.c. The fourth group of diabetic rats remained untreated for the duration of the experiment. A preliminary study was conducted to determine an appropriate T 3 dose in diabetic SHR. 19 An initial T 3 dose of 30 ^g/kg/day 15 resulted in elevated systolic arterial pressure and heart rate compared with untreated nondiabetic rats. The T 3 dose was subsequently reduced to 10 ^.g/kg/day and readjusted to 8 jtg/kg/day after 6 weeks so that heart rates of the treated, diabetic rats matched those of the nondiabetic controls (see Figure IB) . The nondiabetic rats were also subdivided: untreated, foodrestricted, or T 3 (8-10 Aig/kg/day s.c). The foodrestricted rats were housed individually, and their food allowance was adjusted so that their weights were similar to those of the diabetic group.
In Vivo Measurements
Weekly measurements of systolic arterial pressure, heart rate, and body weight were taken just before the tail vein injections and then for 8 subsequent weeks. Systolic arterial pressure and heart rate were obtained in triplicate using standard tail-cuff sphygmomanometry after the rats were placed in a temperature-controlled chamber (34° C) for 10-15 minutes. These measurements were recorded before the daily injections of T 3 or insulin and after the food-restricted group was fed.
Serum Assays
The rats were killed by rapid decapitation 8 weeks after the STZ or citrate buffer injections. The serum samples were collected 15-18 hours subsequent to the final insulin or T 3 injection and stored at -80° C for future determinations. The degree of diabetes was assessed by serum glucose values using a glucose oxidase assay (Sigma Chemical Co.). Rats were considered diabetic if serum glucose concentrations exceeded 300 mg/dl. Serum immunoreactive insulin activity, total T 3 , and total thyroxine (T 4 ) were determined by radioimmunoassay (Cambridge Medical Diagnostics, Billerica, Massachusetts). Serum levels of insulin were quantified using rat insulin (generously provided by Dr. R. Chance of Eli Lilly, Inc.) as a standard.
Cardiac Performance
The hearts were quickly removed and perfused as described previously. 6 In brief, the perfusion apparatus was designed to allow manipulations in both volume loading, that is, left atrial filling pressure (LAFP), and pressure loading (resistance to aortic ejection). Left ventricular pressure (LVP) and aortic pressure were monitored continually through indwelling cannulae coupled to pulse transducers (Statham, Hato Rey, Puerto Rico). Aortic flow rate (AFR) and coronary flow rate (CFR) were quantified intermittently. Myocardial oxygen consumption (VO2) was assessed with an in-line O 2 electrode (Transidyne Corp., Ann Arbor, Michigan) confluent with the coronary perfusate (see calculations below).
Hearts were perfused with nonrecirculating KrebsHenseleit buffer maintained at 37° C. The buffer contained (mM) NaCl 120, KC1 
Heart Weight Ratios
Once the data were collected, the hearts were removed from the perfusion apparatus and blotted dry. The aorta was removed, and the following wet weights were obtained: whole heart, left ventricular including the septum, and right ventricular. These weights were used to assess the degree of left ventricular hypertrophy. 6 
Calculations
Direct measurements included LVP, left ventricular end-diastolic pressure (EDP), AFR, CFR, aortic pressures (including mean aortic pressure), and Po 2 of the coronary effluent. Indexes of heart performance included left ventricular pulse pressure (LVPP as maximum LVP minus EDP), maximum rate of left ventricular pressure generation (LV+dP/dt), hydraulic power (power as the product of LVPP and cardiac output [cardiac output=AFR plus CFR] per gram heart weight) and stroke work (stroke work as the ratio of power to heart rate). Vcŵ as calculated as the product of oxygen extracted from the buffer, CFR, and oxygen solubility in buffer at 37° C (31.25 ^1/cm 3 ) and normalized for heart weight. The efficiency of contraction was then calculated as the ratio of power to VO2. Coronary vascular resistance (CVR) was estimated from the slope of the regression line when mean aortic pressure was plotted against CFR at the four pressure loads. 6 
Statistical Analyses
The differential effects of diabetes and the hormone treatments were evaluated by analysis of variance (with repeated measures where appropriate), and the Student-Newman-Keuls test for multiple comparisons (Statistical Analysis System, Cary, North Carolina). Group means were considered statistically different from each other if the probability value was less than 0.05. Lower probabilities were not reported. All group comparisons were made statistically; however, in most cases it was only necessary to present comparisons of each experimental group to the untreated, nondiabetic SHR. Additional comparisons, between experimental groups, were noted only if they had obvious relevance to the discussion.
Results
Serum Assays
Serum glucose levels were elevated in all STZinjected groups except those that had been pretreated with OMG (Table 1) . Treatment with PZI controlled the hyperglycemia more effectively than LI did, but neither treatment restored serum glucose levels to that of the nondiabetic rats. Glucose levels of the food-restricted and T 3 -treated nondiabetic SHR were not different from those of the untreated, nondiabetic group. Hypoinsulinemia was evident in both the untreated and the T 3 -treated diabetic rats. Both PZI and LI treatments markedly elevated serum immunoreactive insulin activity; PZI effected the most pronounced increase. The elevated levels may reflect a subsensitivity to exogenous insulin in the diabetic rat. The serum insulin levels of all the other groups were normal.
Diabetes also reduced serum T 3 and T 4 levels. Either insulin or T 3 treatment prevented the decline in T 3 concentration. Insulin treatment also reversed the drop in T 4 levels. However, T 3 treatment of either diabetic or nondiabetic SHR markedly suppressed serum T 4 concentrations. The OMG and foodrestricted groups had normal T 3 values, but the foodrestricted group had slightly depressed T 4 levels.
Body and Heart Weights
Diabetes reduced both heart and body weights of SHR (Table 2) . Treatment with PZI completely prevented these changes, whereas LI was only partially effective. In contrast, T 3 therapy did not affect the decline in heart weight but increased the extent of the loss in body weight of diabetic SHR. Administration of T 3 to nondiabetic SHR had no effect on body weight or heart weight. The effects of STZinduced diabetes on body weight and heart weight were nearly duplicated by food restriction and completely blocked by OMG pretreatment.
The ratios heart weight/body weight and left ventricular weight/body weight, which are indexes of relative cardiac hypertrophy, and left ventricular weight/right ventricular weight, which is an index of absolute left ventricular hypertrophy, 6 were not significantly affected by any of the experimental manipulations except one; the extent of relative hypertrophy was increased in the T 3 -treated diabetic group.
Mortality
The mortality rate of the diabetic SHR was about 64%, which was much higher than that of any other group (Table 3) . As expected, insulin treatment (either PZI or LI) prevented the 8-week mortality of diabetic SHR. Unexpectedly, T 3 treatment was as effective as insulin was in preventing (or delaying) mortality of the diabetic rats. The mortality in the food-restricted group occurred early in the study as a result of attempts to exactly duplicate the mean body weight of the diabetic group. Slight upward adjustments of the food allotment prevented further mortality and resulted in mean body weight that was slightly higher than that of the diabetic group by the end of the 8-week period (see Table 2 ). The mortality of diabetic SHR was completely prevented by treatment with OMG before STZ injection.
Systolic Arterial Pressure and Heart Rate
Diabetes depressed systolic arterial pressure of SHR in vivo, beginning about 4 weeks after STZ injection ( Figure 1A ), which confirmed previous results. 6 It also caused a progressive decline in heart rate ( Figure IB) . Either insulin (PZI or LI) or T 3 treatment prevented both the depressor and bradycardic effects of diabetes. Because both PZI and LI restored systolic arterial pressure and heart rate to Values are mean±SD, obtained before (Week 0) and 8 weeks after initiation of diabetes or treatment. SAP, systolic arterial pressure; HR, heart rate; Tj, triiodothyronine; I, protamine zinc insulin and lente insulin; FR, food-restricted nondiabetic group; OMG, 3-O-methylglucose pretreated, streptozotocin-injected group.
•Significantly different from the nondiabetic group (p<0.05).
control values, the two insulin-treated groups were pooled in Figure 1 and Table 4 . A summary of the systolic arterial pressure and heart rate measurements in the remaining control groups at the 8-week time point is provided in Table 4 . With one exception, none of these values is significantly different from that of the untreated, nondiabetic group. Only the heart rate of the food-restricted group was significantly depressed.
Cardiac Performance Ex Vivo
Diabetes impaired the performance of SHR hearts ex vivo, under either volume-or pressure-loading conditions (Figures 2 and 3) . The impairment was evident as a decline in LVPP and stroke work at higher volume loads (Figure 2) , and in LVPP at higher pressure loads (Figure 3 
FIGURE 2. Function curves showing cardiac performance ex vivo, as measured by (panel A) left ventricular pulse pressure (LVPP) or (panel B) stroke work (SW), of nondiabetic (nd), diabetic (d), insulin-treated diabetic (d+i), and triiodothyronine T r treated diabetic (d+t 3 ) spontaneously hypertensive rats. Hearts were volume loaded by varying left atrial filling pressure (LAFP) between 5 and 20 cm Hfi. Resistance to left ventricular ejection was fixed at 1.54 kPajcm?lmin. Values are mean±SD, obtained 8 weeks after initiation of diabetes or treatment (n=9 -14 per group). *'Significantly different from the nondiabetic group (p<0.05). **Significantty different from the nondiabetic and diabetic groups ( p<0.05).
( Table 5 ). These results generally confirm those of previous reports, 6 -7 which had also demonstrated that the magnitude of the cardiac impairment due to diabetes is greater in the SHR than it is in normotensive rats. Both insulin treatments of diabetic SHR (either PZI or LI) completely prevented the decline in cardiac performance; in the interest of clarity, therefore, the data for the two insulin-treated groups were pooled in Figures 2 and 3 and in Tables 5-7 . Treatment of diabetic SHR with T 3 was nearly as effective as was insulin therapy ( Figure 4) ; it completely prevented all effects of diabetes except that it only partially maintained LVPP at the highest volume load (Figure 2A and Table 5 ) and depressed LVPP at the lowest pressure load ( Figure 3A ). In addition, T 3 treatment of diabetic rats significantly increased stroke work at a LVFP of 10 cm H 2 O ( Figure 2B ). Neither LVPP, stroke work, nor contractility of any of the other control groups was o a.
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a. Figure 2 .1, protamine zinc insulin or lente insulin; T 3 , triiodothyronine; FR, food-restricted nondiabetic group; OMG, 3-O-methylglucose pretreated, streptozotocininjected group.
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•Significantly different from the nondiabetic group (p<0.05). tSignificantly different from the nondiabetic and diabetic groups (p<0.05).
different from the corresponding value of the nondiDiabetes had no effect on V02, cardiac output, abetic control under either volume-loading (Table 5) hydraulic power, or efficiency of contraction (Table  or pressure-loading conditions (data not shown).
6). None of the experimental groups differed signifThus, neither malnutrition nor direct cardiotoxic icantly from the control with regard to any of these effects of STZ appear to contribute significantly to variables, except that the cardiac output (per gram the cardiac impairments of the diabetic SHR.
heart weight) of the T 3 -treated diabetic group was Values are mean±SD, obtained 8 weeks after initiation of diabetes or treatment. Left atrial filling pressure was fixed at 15 cm H 2 O and resistance to aortic ejection was fixed at 1.54 kPa/cm 3 /min. VOj, myocardial oxygen consumption; CO, cardiac output; E, efficiency of contraction; T 3 , triiodothyronine; I, protamine zinc insulin or lente insulin; FR, food-restricted nondiabetic group; OMG, 3-O-methylglucose pretreated, streptozotocin-injected group.
•Significantly different from the nondiabetic group (p<0.05). Coronary flow rate (CFR) values are mean±SD and coronary vascular resistance (CVR) values are mean±SEM, obtained 8 weeks after initiation of diabetes or treatment. CFR was measured when left atrial filling pressure was fixed at 15 cm H 2 O and resistance to aortic ejection was fixed at 1.54 kPa/crn 3 /min. CVR is determined by plotting mean aortic pressure against coronary flow at the four resistances to aortic ejection and obtaining the slope of the regression (see Methods). I, protamine zinc insulin or lente insulin; T 3 , triiodothyTonine; FR, food-restricted nondiabetic group; OMG, 3-O-methylglucose pretreated, streptozotocin-injected group.
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180 0 TIME (msec) Figure 3A. elevated. This was related more to the reduction in heart size than it was to any increase in total output. 20 Although diabetes reduced total CFR, it had no effect on either CFR per gram heart weight or on CVR (Table 7) . Thus, the impaired LVPP, stroke work, and contractility of diabetic SHR hearts were not associated with restricted coronary flow.
FIGURE 4. Left ventricular pressure (LVP) waves from perfused working hearts of nondiabetic, diabetic, insulintreated diabetic, and triiodothyronine (T 3 )-treated diabetic spontaneously hypertensive rats (SHR), under incremental pressure-loading conditions. Each of the four superimposed LVP waves was obtained at one of four resistances to
Discussion
Recent results from this laboratory suggested that a low thyroid state might contribute significantly to changes in cardiac performance of diabetic SHR. 617 Accordingly, we expected that T 3 treatment of diabetic SHR might reduce the magnitude of the subsequent impairment in mechanical function. We were somewhat surprised, though, that the dose of T 3 used in this study was almost as effective as insulin was in preventing the depressions in measurements of heart function, including pressure generation, rates of contraction, and stroke work.
Our results obtained from SHR differ from previous reports of the effects of T 3 treatment on cardiac function and hemodynamic measurements in diabetic normotensive rats. 9 -1415 In the earlier studies, T 3 treatment at doses ranging from approximately 8 to 30 jig/kg/day was either ineffective or partially effective in preventing diabetes-induced myocardial functional impairments. For the present study, we selected the dose of T 3 according to its ability to maintain normal heart rate in vivo, an index that is a sensitive indirect indicator of thyroid status. This turned out to be about twofold to threefold greater than "physiological" replacement doses in nonhypertensive rat strains. 21 The T 3 dose used herein did not appear, however, to impose a hyperthyroid condition in diabetic SHR for several reasons: 1) it did not elevate serum T 3 levels above normal, when measured at the same time point after injection, in either the diabetic or the nondiabetic SHR groups (Table  1) ; 2) the same dose given to nondiabetic SHR (Table 4) or to diabetic Sprague-Dawley rats 22 had no effect on systolic arterial pressure or heart rate in vivo; and 3) T 3 treatment of nondiabetic SHR had no effect on any of the indexes of cardiac performance ex vivo (Tables 5-7 ). Although T 3 treatment reduced body weights of the diabetic SHR, it had no effect on this measurement in the nondiabetic control group (Table 2) . It may not be appropriate to assume that doses of T 3 that are adequate for therapy of simple hypothyroidism should be enough to correct the hypothyroid state induced by diabetes. Diabetic hypothyroidism in the rat is characterized not only by low serum hormone levels, but also by target tissue resistance. For example, diabetes impairs peripheral T 4 to T 3 conversion, tissue T 3 uptake, and both affinity and density of nuclear T 3 receptors. 23 ' 24 The differences in the effects of T 3 treatment between the SHR and normotensive diabetic rats are probably related to the elevated arterial pressure of SHR and not to differences related specifically to the genetic strain. We have preliminary results (unpublished observations from our laboratory) that T 3 is as effective in the diabetic renovascular hypertensive rat as it is in the diabetic SHR. A common feature of the two models, left ventricular hypertrophy, may increase cardiac susceptibility to a number of stresses including those imposed by diabetes, 467 hypothyroidism, 12 or ischemia. 25 Our results suggest that the hypothyroidism accompanying diabetes has a more profound cardiovascular effect in animals with elevated arterial pressure and that hypertrophied myocardium may be functionally more dependent on thyroid status than is nonhypertrophic heart muscle. This hypothesis is supported by the observation that thyroidectomy reduces left ventricular contractility to a greater extent in the SHR than it does in the Wistar-Kyoto rat. 17 There are a number of mechanisms by which T 3 treatment might effectively reverse the cardiac functional impairments of diabetes, especially of hypertrophic heart muscle. 26 A common manifestation of diabetes, hypertrophy, and hypothyroidism on rat ventricular muscle is a shift from the predominant V[ to the V 3 myosin isozyme. 29 The effects of hypertension and diabetes (with or without hypothyroidism) on myosin isozyme profiles may thus be additive, but this hypothesis has not been tested. T 3 treatment of the diabetic SHR may change the ratio of myosin isozyme activity in favor of V! and this may in turn help to explain the increased left ventricular contractility in this group (Table 5 31 These in turn have been linked to changes in energy substrate availability and membrane integrity and function in the heart. 10 Hypertrophy may exacerbate these metabolic effects. Increased vulnerability of hypertrophic myocardium to metabolic stress may be related either to a lower energy state 32 or to abnormal lipid metabolism in the SHR.
-
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- 35 Interestingly, the vasodilator hydralazine reduced serum lipids and improved cardiac function but also corrected the attendant hypothyroid state in diabetic nonhypertensive rats. 36 Thyroid hormone may relieve some of these stresses in diabetic SHR, perhaps by increasing the use of fatty acid by the myocardium, 37 by stimulating glucose uptake and use, 38 or by augmenting glucoseinduced insulin secretion, 39 although our data (Table  1) did not support the latter possibility. Thyroid hormone may also enhance the responsiveness of the myocardium to sympathoadrenal influences (see below).
Several alternative interpretations of our results could be eliminated by the control studies. Amelioration of the cardiodepression and mortality by either insulin or T 3 treatment, and by pretreatment with the glucose analogue OMG, 18 ruled out the possibility that direct cardiotoxicity of STZ contributed to the morbidity and mortality of diabetes. Complete glycemic control was not necessary for preservation of cardiac functional activity, which supported previous observations 35 -40 ; both PZI and LI maintained pump function without normalizing serum glucose values (Table 1) . Malnutrition alone could not account for the observed cardiodepressive effects of diabetes in our study, as performance was not impaired in the food-restricted group (Tables 5 and 6; see also References 3 and 6) .
The sustained hypertension of T 3 -treated diabetic SHR (Table 4) suggests that attendant hypothyroidism may have contributed to the decline in systolic arterial pressure of the untreated rats. This is supported by the effectiveness of thyroidectomy in antagonizing hypertension in this model, 1617 and by the ability of thyroid hormone treatment to reverse the effect. 16 The mechanism may involve a predominant effect of T 3 on the myocardium rather than on the vasculature. Indirect evidence suggests that the depressor effect of diabetes in SHR is associated with a decline in total peripheral vascular resistance (TPR). 41 However, in other models, hypothyroidism may be associated with increased TPR, and hyperthyroidism with reduced TPR. 26 The hypertension of hyperthyroid rats has been attributed primarily to the cardiac, rather than the vascular, effects of T 3 . 42 Variations in systolic arterial pressure of either diabetic or hypothyroid SHR, whether treated or untreated, always seem to be associated with parallel changes in heart performance 6 -7 -17 (Tables 4 and 5 ). Treatment with T 3 , like insulin, also corrected the bradycardia of diabetic SHR ( Figure IB) . The bradycardia associated with either diabetes or hypothyroidism has been attributed, at least in part, to depressed myocardial responsiveness to adrenergic stimulation. 13 - 43 Both hypertrophic 44 and diabetic 45 myocardium have been shown to possess a lower density of functional ^-adrenergic receptors, and both insulin and T 3 may be involved in the regulation of cardiac ^adrenergic receptor density. Insulin may act indirectly by restoring serum T 3 levels. Depressed myocardial /3-adrenergic receptor numbers of diabetic Sprague-Dawley (SD) rats were restored to normal with either insulin or T 4 treatment, whereas those of diabetic rats subjected to thyroidectomy were not affected by insulin treatment alone. 4 * Higher doses of insulin may also stimulate the sympathetic nervous system independent of associated changes in blood glucose. 47 The chronotropic action of T 3 in vivo may also involve a direct effect of the hormone on pacemaker cells. 48 The available evidence implies that at least a significant portion of the bradycardia of experimental diabetes, in the presence or absence of hypertension, can be attributed to the attendant hypothyroidism.
In conclusion, the cardiac impairments associated with diabetes in the SHR can be prevented by either insulin or T 3 treatment. To our knowledge, this is the first account of a moderate dose of T 3 successfully restoring cardiac performance in experimental diabetes. In addition, T 3 treatment, like insulin, prevented the fall in arterial pressure and bradycardia induced by diabetes in the SHR in vivo and either reduced or delayed mortality. The results suggest that attendant hypothyroidism may play a more significant role in the development of impaired cardiac function in diabetic SHR than it does in normotensive rats. The possible contribution of left ventricular hypertrophy to this phenomenon remains to be studied. These results may have some clinical applicability. Whether hypertension occurs more frequently among diabetic patients or not, 49 it is generally regarded as an important risk factor for the higher cardiovascular morbidity and mortality in this group. among diabetics may be as high as 30%, is most severe during poor metabolic control, and is most evident in insulin-dependant diabetes mellitus. 23 Although diabetic patients with hypothyroidism may be at increased risk of cardiovascular morbidity and mortality, 50 this risk may be further intensified by hypertension.
